B40.9 Blastomycosis, unspecified

Name of the Condition

• Blastomycosis, unspecified

Summary

Blastomycosis, unspecified is a fungal infection caused by Blastomyces dermatitidis (and related species) that primarily affects the lungs but can disseminate to other body sites. The condition may present as an acute or chronic pulmonary infection, with potential for systemic involvement in severe cases. Clinical manifestations range from asymptomatic infection to severe, life-threatening disease, particularly in immunocompromised individuals.

Causes

The infection is caused by inhaling airborne spores of Blastomyces fungi, which are found in soil and decaying organic matter (e.g., wood, leaves) in endemic regions. The spores convert to yeast in the lungs, where they multiply and may spread hematogenously to other organs, including the skin, bones, and central nervous system. Direct inoculation (e.g., through skin wounds) is rare.

Risk Factors

• Residence in or travel to endemic areas (e.g., parts of North America, particularly the Ohio and Mississippi River valleys).
• Occupational or recreational exposure to soil (e.g., construction, forestry, gardening).
• Immunocompromised states (e.g., HIV/AIDS, organ transplantation, chronic steroid use).
• Male gender (higher incidence reported).
• Advanced age.

Symptoms

• Pulmonary: Cough (productive or non-productive), chest pain, dyspnea, fever, night sweats, weight loss.
• Systemic: Fatigue, myalgia, arthralgia.
• Disseminated disease may involve skin (e.g., nodules, ulcers), bones, or central nervous system.

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging (e.g., chest X-ray or CT), and laboratory testing. Sputum or tissue samples may be examined for fungal elements, cultured for Blastomyces, or tested via molecular methods (e.g., PCR). Biopsy of affected tissues (e.g., skin, lung) may be performed to confirm infection, especially in disseminated cases. Serologic tests are available but may have limitations in sensitivity and specificity.

Treatment Options

Treatment depends on disease severity and site of infection. Mild to moderate pulmonary disease may be managed with oral antifungal therapy (e.g., itraconazole) for 6–12 months. Severe or disseminated disease often requires initial intravenous amphotericin B, followed by oral therapy. Immunosuppressed patients may need longer treatment durations. Surgical intervention may be necessary for complications like abscesses or bone lesions.

Prognosis and Follow-Up

Prognosis varies based on disease extent, host immunity, and timeliness of treatment. Most immunocompetent patients with localized disease recover fully with appropriate therapy. Disseminated or severe infections, particularly in immunocompromised individuals, carry higher risks of mortality or long-term sequelae. Follow-up includes monitoring for treatment response, symptom resolution, and potential recurrence, with repeat imaging or laboratory testing as clinically indicated.

Complications

• Acute respiratory failure (in severe pulmonary disease).
• Dissemination to skin, bones, or central nervous system.
• Chronic lung damage (e.g., fibrosis, cavitation).
• Secondary bacterial infections.
• Neurological deficits (if central nervous system is involved).

Lifestyle & Prevention

• Avoid disturbing soil in endemic areas (e.g., during construction or outdoor activities).
• Wear masks or respiratory protection when exposure to dust or decaying matter is unavoidable.
• Promptly clean and cover skin wounds to reduce risk of direct inoculation.
• Maintain overall health to support immune function.

When to Seek Professional Help

Seek medical attention if you experience persistent respiratory symptoms (e.g., cough, chest pain, fever) after potential exposure to endemic environments, or if symptoms worsen despite initial care. Immediate evaluation is critical for severe symptoms (e.g., difficulty breathing, confusion) or signs of systemic spread (e.g., skin lesions, unexplained weight loss).

Tips for Medical Coders

Use B40.9 for cases of blastomycosis where the site or clinical course (acute/chronic) is not specified. Document whether the infection is localized (e.g., pulmonary) or disseminated, as this may impact coding specificity in related encounters. Ensure clinical documentation supports the unspecified designation to align with coding guidelines.